WO2020207476A1 - 一种吡唑并吡嗪衍生的化合物、药物组合物以及其用途 - Google Patents
一种吡唑并吡嗪衍生的化合物、药物组合物以及其用途 Download PDFInfo
- Publication number
- WO2020207476A1 WO2020207476A1 PCT/CN2020/084243 CN2020084243W WO2020207476A1 WO 2020207476 A1 WO2020207476 A1 WO 2020207476A1 CN 2020084243 W CN2020084243 W CN 2020084243W WO 2020207476 A1 WO2020207476 A1 WO 2020207476A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- group
- amino
- alkyl
- cyano
- haloalkyl
- Prior art date
Links
- PINVCRAZGLSROU-UHFFFAOYSA-N CC(c1c[n](C)nc1)=O Chemical compound CC(c1c[n](C)nc1)=O PINVCRAZGLSROU-UHFFFAOYSA-N 0.000 description 1
- LHLUUJOYQYTQMV-UHFFFAOYSA-N CCS(N(C1)CC1(CC#N)[n](cc1B2OC(C)(C)C(C)(C)O2)nc1N)(=O)=O Chemical compound CCS(N(C1)CC1(CC#N)[n](cc1B2OC(C)(C)C(C)(C)O2)nc1N)(=O)=O LHLUUJOYQYTQMV-UHFFFAOYSA-N 0.000 description 1
- PCODQZSEJGUTFG-UHFFFAOYSA-N C[n]1ncc(-c2c[n]3ncc(I)c3c(Cl)n2)c1 Chemical compound C[n]1ncc(-c2c[n]3ncc(I)c3c(Cl)n2)c1 PCODQZSEJGUTFG-UHFFFAOYSA-N 0.000 description 1
- 0 C[n]1ncc(-c2c[n]3nccc3c(*)c2)c1 Chemical compound C[n]1ncc(-c2c[n]3nccc3c(*)c2)c1 0.000 description 1
- NDFBBDUBZDNHGS-UHFFFAOYSA-N C[n]1ncc(-c2c[n]3nccc3c(Cl)n2)c1 Chemical compound C[n]1ncc(-c2c[n]3nccc3c(Cl)n2)c1 NDFBBDUBZDNHGS-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Definitions
- the invention relates to the field of medicine, in particular to a pyrazolopyrazine-derived compound, a pharmaceutical composition and its use.
- JAK/STAT signal pathway is a signal transduction pathway stimulated by cytokines, which participates in many important biological processes such as cell proliferation, differentiation, apoptosis and immune regulation.
- JAK kinase contains 4 family members, namely JAK1, JAK2, JAK3 and Tyk2. The activation of this signaling pathway is closely related to the occurrence and development of many diseases, including various inflammatory diseases, lymphoma, leukemia and solid tumors.
- Ruxolitinib jointly developed by Incyte and Novartis was approved for the treatment of polycythemia vera (PCV) in November 2011; Tofacitnib from Pfizer was approved for the treatment of rheumatoid joints in November 2012 Inflammation (RA) was later approved for the treatment of psoriatic arthritis and ulcerative colitis; Baricitinib, jointly developed by Incyte and Eli Lilly, was approved to treat rheumatoid arthritis in May 2018; in addition, The oral formulation Oclacitinib developed by Zoetis was approved in May 2013 for the treatment of canine atopic dermatitis.
- JAK inhibitors have also made good progress in other indications such as atopic dermatitis, psoriasis, and alopecia areata.
- the main factors involved in the pathogenesis of psoriasis include changes in the functions of T cells, dendritic cells, keratinocytes, mast cells and macrophages. These cells and their related cytokines and chemokines interact to mediate A series of inflammatory reactions, epidermal proliferation, hypokeratosis, spinous hypertrophy, vascular changes, etc.
- the main related targets are tumor necrosis factor- ⁇ (TNF- ⁇ ), phosphodiesterase 4 (PDE4), JAK kinase And interleukins and their receptors (IL&ILR), etc.
- IL-12, IL-17 and IL-23 are the main targets of psoriasis drugs in the IL family. Targeting the downstream effector molecule Tyk2 of IL-12/23 is a good research direction. Because the expression of Tyk2 in dendritic cells is necessary for the production of IL-12, IL-23 and IFN- ⁇ and the induction of Th1 cell differentiation (Blood, 2007), IL-23 secreted by dendritic cells can induce Th17 cells secrete inflammatory mediators, such as IL-17A, IL-17F, IL-22 and so on. These inflammatory mediators will promote the activation and hyperproliferation of epidermal keratinocytes (KC).
- KC epidermal keratinocytes
- activated KC cells produce substances such as pro-inflammatory factors, chemokines and antibacterial peptides, which can recruit and activate immune cells to the site of inflamed skin. This leads to an expansion of the immune response and eventually develops into clinical symptoms associated with psoriasis. This shows that Tyk2 plays a very important role in the occurrence and development of psoriasis, and targeted inhibition of Tyk2 is expected to control the disease at the initial stage of inflammation.
- An object of the present invention is to provide a novel pyrazolopyrazine-derived compound or a pharmaceutically acceptable salt, solvate, active metabolite, polymorph, isotope label, isomer or prodrug thereof , Has excellent JAK enzyme inhibitory activity.
- Another object of the present invention is to provide a pharmaceutical composition.
- Another object of the present invention is to provide the use of the above compound or a pharmaceutically acceptable salt, solvate, active metabolite, polymorph, isotope label, isomer or prodrug thereof.
- the present invention provides a compound represented by general formula (AI) or a pharmaceutically acceptable salt, solvate, active metabolite, polymorph, isotope label or isomer thereof,
- WR 1 means -(CR 5 R 1 )- or -(NR 1 )-;
- R" represents C 1 -C 6 alkyl substituted with hydroxy, methoxy or amino
- R represents halogen, substituted or unsubstituted -NR 9 R 10 , or R'and R and the atoms on the ring to which they are connected together form a six-membered or five-membered aromatic ring or heteroaromatic ring;
- XR' represents -(N)- or -(CR')-, where, when XR' represents -(CR')-, R'and R and the atoms on the ring to which they are connected together form a six-membered or five-membered Aromatic or heteroaromatic ring;
- YR 3 represents -(N)- or -(CR 3 )-;
- Z represents -N- or -CR 3 -;
- R 1 represents -(CH 2 ) n -R 1 '
- R 1 ' represents substituted or unsubstituted hydrogen, halogen, C 1-6 alkyl, C 1-6 alkoxy, C 1-6 haloalkyl, hydroxyl , mercapto, amino, cyano, C 3 ⁇ 8 cycloalkyl, C 3 ⁇ 8 heterocyclyl, C 6 ⁇ 20 aryl group, C 3 ⁇ 20 heteroaryl, -NR 9 COR 10, -CONR 9 R 10 , -COR 9 , -SOR 9 or -SO 2 R 9 , n represents an integer from 0 to 4;
- R 2 to R 5 each independently represent substituted or unsubstituted hydrogen, halogen, C 1-6 alkyl, C 1-6 alkoxy, C 1-6 haloalkyl, hydroxyl, mercapto, amino or cyano;
- R 8 represents -(CH 2 ) n -R 8 ', R 8 'represents substituted or unsubstituted hydrogen, halogen, C 1-6 alkyl, C 1-6 alkoxy, C 1-6 haloalkyl, hydroxyl , Mercapto, cyano or -NR 9 R 10 , n represents an integer from 0 to 4;
- R 9 and R 10 each independently represent substituted or unsubstituted hydrogen, halogen, C 1-6 alkyl, C 1-6 alkoxy, C 1-6 haloalkyl, hydroxyl, mercapto, amino, cyano, C 3-8 cycloalkyl or C 3-8 heterocyclyl;
- the above groups optionally substituted group selected from halogen, C 1 ⁇ 6 alkyl group, C 1 ⁇ 6 haloalkyl, C 1 ⁇ 6 alkoxy group, C 1 ⁇ 6 alkylthio, C 3 ⁇ 8 cycloalkyl, C 3 ⁇ 8 heterocyclyl, C 6 ⁇ 20 aryl group, C 3 ⁇ 20 heteroaromatic group, C 1 ⁇ 6 alkyl group, C 1 ⁇ 6 alkyl group, C 1 ⁇ 6 alkylsulfonyl group, an amino group , Hydroxy, mercapto, carboxy, nitro, amide or cyano.
- the present invention provides a compound represented by general formula (I) or a pharmaceutically acceptable salt, solvate, active metabolite, polymorph, isotope label or isomer thereof,
- WR 1 means -(CR 5 R 1 )- or -(NR 1 )-;
- R represents substituted or unsubstituted -NR 9 R 10 ;
- R 1 represents -(CH 2 ) n -R 1 '
- R 1 ' represents substituted or unsubstituted hydrogen, halogen, C 1-6 alkyl, C 1-6 alkoxy, C 1-6 haloalkyl, hydroxyl , mercapto, amino, cyano, C 3 ⁇ 8 cycloalkyl, C 3 ⁇ 8 heterocyclyl, C 6 ⁇ 20 aryl group, C 3 ⁇ 20 heteroaryl, -NR 9 COR 10, -CONR 9 R 10 , -COR 9 , -SOR 9 or -SO 2 R 9 , n represents an integer from 0 to 4;
- R 2 to R 5 each independently represent substituted or unsubstituted hydrogen, halogen, C 1-6 alkyl, C 1-6 alkoxy, C 1-6 haloalkyl, hydroxyl, mercapto, amino or cyano;
- R 8 represents -(CH 2 ) n -R 8 ', R 8 'represents substituted or unsubstituted hydrogen, halogen, C 1-6 alkyl, C 1-6 alkoxy, C 1-6 haloalkyl, hydroxyl , Mercapto, cyano or -NR 9 R 10 , n represents an integer from 0 to 4;
- R 9 and R 10 each independently represent substituted or unsubstituted hydrogen, halogen, C 1-6 alkyl, C 1-6 alkoxy, C 1-6 haloalkyl, hydroxyl, mercapto, amino, cyano, C 3-8 cycloalkyl or C 3-8 heterocyclyl;
- the above groups optionally substituted group selected from halogen, C 1 ⁇ 6 alkyl group, C 1 ⁇ 6 haloalkyl, C 1 ⁇ 6 alkoxy group, C 1 ⁇ 6 alkylthio, C 3 ⁇ 8 cycloalkyl, C 3 ⁇ 8 heterocyclyl, C 6 ⁇ 20 aryl group, C 3 ⁇ 20 heteroaromatic group, C 1 ⁇ 6 alkyl group, C 1 ⁇ 6 alkyl group, C 1 ⁇ 6 alkylsulfonyl group, an amino group , Hydroxy, mercapto, carboxy, nitro, amide or cyano.
- the present invention provides a compound represented by general formula (I) or a pharmaceutically acceptable salt, solvate, active metabolite, polymorph, isotope label or isomer thereof,
- WR 1 means -(CR 5 R 1 )- or -(NR 1 )-;
- R represents halogen
- R 1 represents -(CH 2 ) n -R 1 '
- R 1 ' represents substituted or unsubstituted hydrogen, halogen, C 1-6 alkyl, C 1-6 alkoxy, C 1-6 haloalkyl, hydroxyl , mercapto, amino, cyano, C 3 ⁇ 8 cycloalkyl, C 3 ⁇ 8 heterocyclyl, C 6 ⁇ 20 aryl group, C 3 ⁇ 20 heteroaryl, -NR 9 COR 10, -CONR 9 R 10 , -COR 9 , -SOR 9 or -SO 2 R 9 , n represents an integer from 0 to 4;
- R 2 to R 5 each independently represent substituted or unsubstituted hydrogen, halogen, C 1-6 alkyl, C 1-6 alkoxy, C 1-6 haloalkyl, hydroxyl, mercapto, amino or cyano;
- R 8 represents -(CH 2 ) n -R 8 ', R 8 'represents substituted or unsubstituted hydrogen, halogen, C 1-6 alkyl, C 1-6 alkoxy, C 1-6 haloalkyl, hydroxyl , Mercapto, cyano or -NR 9 R 10 , n represents an integer from 0 to 4;
- R 9 and R 10 each independently represent substituted or unsubstituted hydrogen, halogen, C 1-6 alkyl, C 1-6 alkoxy, C 1-6 haloalkyl, hydroxyl, mercapto, amino, cyano, C 3-8 cycloalkyl or C 3-8 heterocyclyl;
- the above groups optionally substituted group selected from halogen, C 1 ⁇ 6 alkyl group, C 1 ⁇ 6 haloalkyl, C 1 ⁇ 6 alkoxy group, C 1 ⁇ 6 alkylthio, C 3 ⁇ 8 cycloalkyl, C 3 ⁇ 8 heterocyclyl, C 6 ⁇ 20 aryl group, C 3 ⁇ 20 heteroaromatic group, C 1 ⁇ 6 alkyl group, C 1 ⁇ 6 alkyl group, C 1 ⁇ 6 alkylsulfonyl group, an amino group , Hydroxy, mercapto, carboxy, nitro, amide or cyano.
- the present invention also provides a compound represented by general formula (I) or a pharmaceutically acceptable salt, solvate, active metabolite, polymorph, isotope label or isomer thereof,
- WR 1 means -(CR 5 R 1 )- or -(NR 1 )-;
- A represents -OR", where R" represents C 1 -C 6 alkyl substituted with hydroxy, methoxy or amino;
- R represents halogen, substituted or unsubstituted -NR 9 R 10 ;
- R 1 represents -(CH 2 ) n -R 1 '
- R 1 ' represents substituted or unsubstituted hydrogen, halogen, C 1-6 alkyl, C 1-6 alkoxy, C 1-6 haloalkyl, hydroxyl , mercapto, amino, cyano, C 3 ⁇ 8 cycloalkyl, C 3 ⁇ 8 heterocyclyl, C 6 ⁇ 20 aryl group, C 3 ⁇ 20 heteroaryl, -NR 9 COR 10, -CONR 9 R 10 , -COR 9 , -SOR 9 or -SO 2 R 9 , n represents an integer from 0 to 4;
- R 2 to R 5 each independently represent substituted or unsubstituted hydrogen, halogen, C 1-6 alkyl, C 1-6 alkoxy, C 1-6 haloalkyl, hydroxyl, mercapto, amino or cyano;
- R 8 represents -(CH 2 ) n -R 8 ', R 8 'represents substituted or unsubstituted hydrogen, halogen, C 1-6 alkyl, C 1-6 alkoxy, C 1-6 haloalkyl, hydroxyl , Mercapto, cyano or -NR 9 R 10 , n represents an integer from 0 to 4;
- R 9 and R 10 each independently represent substituted or unsubstituted hydrogen, halogen, C 1-6 alkyl, C 1-6 alkoxy, C 1-6 haloalkyl, hydroxyl, mercapto, amino, cyano, C 3-8 cycloalkyl or C 3-8 heterocyclyl;
- the above groups optionally substituted group selected from halogen, C 1 ⁇ 6 alkyl group, C 1 ⁇ 6 haloalkyl, C 1 ⁇ 6 alkoxy group, C 1 ⁇ 6 alkylthio, C 3 ⁇ 8 cycloalkyl, C 3 ⁇ 8 heterocyclyl, C 6 ⁇ 20 aryl group, C 3 ⁇ 20 heteroaromatic group, C 1 ⁇ 6 alkyl group, C 1 ⁇ 6 alkyl group, C 1 ⁇ 6 alkylsulfonyl group, an amino group , Hydroxy, mercapto, carboxy, nitro, amide or cyano.
- R, R 1 ⁇ R 10 , R 1 ′, R 8 ′ and their optional substituents include but are not limited to:
- Hydrogen can be expressed as -H, and can also be replaced with deuterium and tritium equivalents.
- Halogen may include fluorine, chlorine, bromine, and iodine.
- the C 1-6 alkyl group may include methyl, ethyl, n-propyl, isopropyl, 2-methyl-1-propyl, 2-methyl-2-propyl, 2-methyl-1-butane Group, 3-methyl-1-butyl, 2-methyl-3-butyl, 2,2-dimethyl-1-propyl, 2-methyl-1-pentyl, 3-methyl- 1-pentyl, 4-methyl-1-pentyl, 2-methyl-2-pentyl, 3-methyl-2-pentyl, 4-methyl-2-pentyl, 2,2-di Methyl-1-butyl, 3,3-dimethyl-1-butyl, 2-ethyl-1-butyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl , Isopentyl, neopentyl, tert-amyl, hexyl, etc.
- the C 1-6 alkoxy group can be represented as -OC 1-6 alkyl group, wherein the C 1-6 alkyl group includes the groups as defined above; for example, the C 1-6 alkoxy group can include methoxy, ethyl Oxy, n-propoxy, isopropoxy, n-butoxy, isobutoxy, sec-butoxy, tert-butoxy, etc.
- the C 1 ⁇ 6 alkylthio group can be represented as -SC 1 ⁇ 6 alkyl, wherein the C 1 ⁇ 8 alkyl group includes groups as defined above; for example, the C 1 ⁇ 8 alkylthio group can include methylthio, ethyl Sulfur-based etc.
- a C 1-6 haloalkyl group can be represented as a group in which any number of hydrogen atoms in the C 1-6 alkyl group is substituted by a halogen, wherein the C 1-6 alkyl group and the group including the halogen are as defined above; for example, , C 1-6 haloalkyl groups may include -CF 3 and the like.
- C 1-6 alkylene groups are divalent functional groups with two substitutable bonds, which can include straight-chain alkylene groups and branched-chain alkylene groups, and straight-chain alkylene groups can be expressed as -(CH 2 ) m -, m represents 1 to 6, and may include, for example, methylene, ethylene and the like.
- C 3 ⁇ 8 cycloalkyl may represent a saturated non-aromatic carbocyclic ring, comprising a single carbon ring (having a ring) carbocyclic ring, and bis (having two rings), e.g., C 3 ⁇ 8 cycloalkyl group may comprise Wait.
- C 3 ⁇ 8 heterocyclyl group may be expressed as the C 3 ⁇ 8 cycloalkyl group, any number of ring atoms is substituted with O, S, N, P, Si , etc.
- the resulting hetero atom group, wherein the C 3 ⁇ The groups included in the 8- cycloalkyl group are as defined above.
- C 3 ⁇ 8 heterocyclic groups may include ethylene oxide group, ethylene sulfide group, a ring nitrogen oxide group, azetidinyl group, a dioxetane group, Thietane, tetrahydrofuranyl, pyrrolidinyl, evil Azolidinyl, tetrahydropyrazolyl, pyrrolinyl, dihydrofuranyl, dihydrothienyl, piperidinyl, tetrahydropyranyl, tetrahydrothiopyranyl, morpholinyl, piperazinyl, dihydro Pyridyl, tetrahydropyridyl, dihydropyranyl, tetrahydropyranyl, dihydrothiopyranyl, azepanyl, oxepanyl, thiepanyl, oxazepine Heterobicyclo[2.2.1]heptyl, azaspiro[2.
- C 6 ⁇ 20 aryl group may include monocyclic aryl, bicyclic aryl group or an aryl group more rings, e.g., may include phenyl, biphenyl, naphthyl, phenanthryl, anthracenyl group, an azulenyl group and the like.
- C 3-20 heteroaryl group may represent O, S, N, P, Si , etc. containing hetero atoms as ring atoms, any number of the resulting unsaturated group, the number of carbon atoms in the heteroaryl group may be 3 to 20 For example, there may be 3, 4, 5, 6, 7, 8, 9, 10, or 10 or more.
- heteroaryl groups may include pyrrolyl, furyl, thienyl, imidazolyl, oxazolyl, pyrazolyl, pyridyl, pyrimidinyl, pyrazinyl, quinolinyl, isoquinolinyl, tetrazolyl, Triazolyl, triazinyl, benzofuranyl, benzothienyl, indolyl, isoindolyl, etc.
- the hydroxyl group can be expressed as -OH.
- the mercapto group can be represented as -SH.
- the nitro group can be expressed as -NO 2 .
- the cyano group can be represented as -CN.
- the carboxyl group can be represented as -COOH, and the H of the carboxyl group can also be substituted by a substituent to form the corresponding ester group, which can be represented as -COOR a .
- the definition of Ra can be all the substitutions described in the general formulas (AI) and (I)
- the definition of the group, for example, an ester group substituted with a C 1-6 alkyl group can be represented as a -COOC 1-6 alkyl group, wherein the C 1-6 alkyl group includes the groups as defined above.
- the ester group is a C 1-4 alkyl ester group
- the C 1-4 alkyl group may include all groups with carbon atoms of 1-4 in the aforementioned definition of "C 1-6 alkyl”.
- the sulfonyl group can be represented as -S(O) 2 R a
- the definition of Ra can be the definition of all the substituents described in the general formulas (AI) and (I), for example, C 1-6 alkyl substituted sulfonyl groups , Can be represented as -S(O) 2 C 1-6 alkyl group, wherein the C 1-6 alkyl group includes groups as defined above.
- the sulfonyl group is a C 1-4 alkylsulfonyl group
- the C 1-4 alkyl group may include all groups with carbon atoms of 1-4 in the aforementioned definition of "C 1-6 alkyl group”.
- the acyl group can be represented as -COR a , and the definition of Ra can be the definition of all the substituents described in the general formulas (AI) and (I).
- an acyl group substituted with a C 1-6 alkyl group can be represented as -COC 1 ⁇ 6 alkyl, wherein the C 1-6 alkyl includes groups as defined above.
- the acyl group is a C 1-4 alkyl acyl group
- the C 1-4 alkyl group may include all the groups with the number of carbon atoms of 1-4 in the aforementioned definition of "C 1-6 alkyl group”.
- Amino group can be represented as -NH 2 , -NHR a or -N(R a ) 2 , and the definition of Ra can be the definition of all substituents described in general formulas (AI) and (I), for example, C 1 ⁇ 6
- the alkyl-substituted amino group can be represented as -NHC 1-6 alkyl or -N(C 1-6 alkyl) 2 , wherein the C 1-6 alkyl includes the same groups as defined above.
- the amino group is a C 1-4 alkylamino group
- the C 1-4 alkyl group may include all groups with carbon atoms of 1-4 in the aforementioned definition of "C 1-6 alkyl group”.
- the amide group can be represented as a -CO amino group, where the amino group is as defined above.
- C 1-4 alkyl may include methyl, ethyl, n-propyl
- C 1-6 alkyl group such as alkyl group, isopropyl group, n-butyl group, isobutyl group, sec-butyl group, tert-butyl group, etc., meets all groups with carbon number of 1-4.
- each group such as C, H, O, N, S, etc.
- hydrogen can be replaced with deuterium, tritium, etc.
- C 1-6 alkane The group can be replaced with a C 1-6 deuterated alkyl group, including but not limited to deuterated methyl, deuterated ethyl, deuterated n-propyl, deuterated isopropyl, deuterated n-butyl, deuterated isobutyl, Deuterated sec-butyl, deuterated tert-butyl, etc.
- the choice of X, Y, and Z needs to make the formed five-membered ring an unsaturated ring.
- the ring may contain one or two double bonds, and adjacent groups need to satisfy the valence state. Claim.
- A may represent one of the following groups:
- A may represent the following groups:
- A may represent the following groups:
- R may represent -NH 2 .
- R 1 represents -(CH 2 ) n -R 1 ', n may represent 0 or an integer other than 0; when n represents 0, R 1 'is R 1 ; When n represents an integer other than 0, it can be 1, 2, 3, or 4, and -(CH 2 ) n -is a linear or branched alkylene group; preferably, n can represent 1 or 2.
- R 1 ' may further represent hydrogen, C 1-4 alkyl, C 1-4 alkoxy, C 1-4 haloalkyl, hydroxyl, cyano, C 3-6 ring Alkyl, C 3-5 heteroaryl, -COR 9 or -SO 2 R 9 ; wherein R 9 represents C 1-4 alkyl, C 1-4 alkoxy, C 1-4 haloalkyl or C 3 ⁇ 6 cycloalkyl.
- R 1 ' when R 1 'represents a C 3 to 5 heteroaryl group, it can represent a heteroaryl group containing N atoms as heteroatoms, and the number of N atoms can be 1, 2 or 3; for example, it can be pyrazole Group, pyridyl, pyrimidinyl, pyrazinyl, triazolyl, triazinyl, etc.
- the compound may be selected from the following structures:
- the present invention also provides a pharmaceutical composition
- a pharmaceutical composition comprising the compound described in any one of the above technical solutions or a pharmaceutically acceptable salt, solvate, active metabolite, polymorph, isotope label or isomer thereof Body, and a pharmaceutically acceptable carrier.
- the pharmaceutical composition may be any common dosage form such as oral dosage form and injection dosage form. Including but not limited to oral dosage forms, parenteral dosage forms, topical dosage forms, rectal dosage forms and the like.
- the pharmaceutical composition may be oral tablets, capsules, pills, powders, sustained-release preparations, solutions and suspensions, sterile solutions, suspensions or emulsions for parenteral injection, and ointments for external use. , Creams, gels, etc., or suppositories for rectal administration.
- the present invention also provides the above-mentioned compounds or their pharmaceutically acceptable salts, solvates, active metabolites, polymorphs, isotope markers, isomers or prodrugs, and the above-mentioned pharmaceutical compositions in preparation for treatment
- JK Janus Kinase
- the JAK enzyme-mediated diseases include tumors or autoimmune diseases.
- the JAK enzyme-mediated diseases may include, but are not limited to, leukemia, non-small cell lung cancer, colon cancer, lymphoma, myeloproliferative tumor, myelodysplastic syndrome and other tumor diseases; also include but not limited to rheumatoid Arthritis, psoriatic arthritis, graft-versus-host disease, non-infectious uveitis, Crohn's disease, ulcerative colitis, ankylosing spondylitis, autoimmune skin diseases and other autoimmune diseases.
- the JAK enzyme-mediated diseases may include, but are not limited to, autoimmune diseases such as psoriasis, atopic dermatitis, vitiligo, pruritus, scleroderma, alopecia areata, alopecia areata, alopecia areata, androgenic alopecia.
- autoimmune diseases such as psoriasis, atopic dermatitis, vitiligo, pruritus, scleroderma, alopecia areata, alopecia areata, alopecia areata, androgenic alopecia.
- sexual skin disease such as psoriasis, atopic dermatitis, vitiligo, pruritus, scleroderma, alopecia areata, alopecia areata, alopecia areata, androgenic alopecia.
- the lymphoma of the present invention may include, but is not limited to, Hodgkins disease (Hodgkins disease) or non-Hodgkins lymphoma (Non-Hodgkins leukemia), and the non-Hodgkins lymphoma includes but is not limited to B -Cell lymphoma (B-cell lymphoma) or T-cell lymphoma (T-cell lymphoma).
- Hodgkins disease Hodgkins disease
- non-Hodgkins lymphoma Non-Hodgkins leukemia
- B-cell lymphoma B -Cell lymphoma
- T-cell lymphoma T-cell lymphoma
- the leukemia of the present invention includes, but is not limited to, Acute lymphoblastic leukemia, Chronic lymphocytic leukemia, Acute myeloid leukemia, Chronic myelocytic leukemia.
- the myelodysplastic syndrome (Myelodysplastic Syndrome) and myeloproliferative neoplasm (Myeloproliferative Neoplasm) of the present invention include but not limited to myelofibrosis, primary myelofibrosis, and primary thrombocytosis Myelofibrosis (Post-essential Thrombocythemia Myelofibrosis), Polycythemia Vera Myelofibrosis (Post-polycythemia Vera Myelofibrosis), Essential Thrombocythemia, Polycythemia Vera (Polycythemia Vera), Multiple Bone Marrow Tumor (Multiple Myeloma).
- the tumors of the present invention also include but are not limited to non-small cell lung cancer, small cell lung cancer, liver cancer, kidney cancer, prostate cancer, breast cancer, pancreatic cancer, gastric cancer, colon cancer, melanoma, head and neck cancer Cancer and other solid tumors.
- the autoimmune diseases of the present invention include but are not limited to rheumatoid arthritis (Rheumatoid Arthritis), juvenile idiopathic arthritis (Juvenile Idiopathic Arthritis), juvenile dermatomyositis (Juvenile Dermatomyositis), atopic dermatitis (Atopic Dermatitis, Giant Cell Arteritis, Takayasu Arteritis, Kawasaki Disease, Herpes Zoster, Autoinflammatory Syndromes, Ankylosing Spondylitis (Ankylosing Spondylitis), Aicardi-Goutines Syndrome (Aicardi-Gout cherries Syndrome), Alopecia Areata (Alopecia Areata), Alopecia Totalis, Alopecia Universalis, Androgenetic Alopecia (Androgenetic Alopecia), Behcet's Disease (Behcet's Disease/ Syndrome), CANDLE syndrome (Chronic Atypical Neutrophilic Dermatosis With Lipodystrophy and Elevated Temperature), Graf
- the use described in the present invention is a use in the preparation of drugs for treating diseases mediated by Tyk2 kinase.
- the pyrazolopyrazine-derived compound and its pharmaceutical composition provided by the present invention have significant JAK kinase inhibitory activity and excellent pharmacokinetic properties, in particular, they have high Tyk2 enzyme inhibitory activity and selectivity to JAK2, It can reduce the toxicity caused by JAK2 inhibition, so it has great application potential.
- the present invention relates to a method for treating a disease mediated by Janus Kinase (JAK), the method comprising administering to a subject in need of such treatment an effective amount of the pyrazolopyrazine derivative provided by the present invention Compound and its pharmaceutical composition.
- JK Janus Kinase
- Standard techniques can be used for reconstitution DNA, oligonucleotide synthesis, and tissue culture and transformation (such as electroporation, lipid infection).
- tissue culture and transformation such as electroporation, lipid infection.
- a kit with instructions provided by the manufacturer can be used, or according to methods known in the art, or The reaction and purification techniques are carried out according to the method described in the present invention.
- the aforementioned techniques and steps can be carried out by conventional methods well known in the art and described in various general documents or more specific documents. The invention is cited and discussed.
- substituent When a substituent is described by a conventional chemical formula written from left to right, the substituent also includes chemically equivalent substituents obtained when the structural formula is written from right to left. For example, CH 2 O is equivalent to OCH 2 .
- substituted means that any one or more hydrogen atoms on a specific atom are replaced by a substituent, as long as the valence of the specific atom is normal and the compound after substitution is stable.
- any variable such as R
- its definition in each case is independent.
- the group may optionally be substituted with up to two Rs, and R has independent options in each case.
- combinations of substituents and/or variants thereof are only permitted if such combinations result in stable compounds.
- C m to n means that there are m to n carbon atoms in this part.
- the "C 1 ⁇ 6 " group means that the part has 1-6 carbon atoms, that is, the group contains 1 carbon atom, 2 carbon atoms, 3 carbon atoms... 6 carbons. atom. Therefore, for example, "C 1-6 alkyl” refers to an alkyl group containing 1-6 carbon atoms, that is, the alkyl group is selected from methyl, ethyl, propyl, isopropyl, n-butyl, Isobutyl, sec-butyl, tert-butyl...etc.
- 1-6 refer to each integer in the given range, for example, "1-6 carbon atoms” means that the group can have 1 carbon atom, 2 carbon atoms, 3 Carbon atoms, 4 carbon atoms, 5 carbon atoms, or 6 carbon atoms.
- pyridine is a six-membered ring and pyrrole is a five-membered ring.
- pharmaceutically acceptable refers to those compounds, materials, compositions and/or dosage forms that are within the scope of reliable medical judgment and are suitable for use in contact with human and animal tissues without excessive Toxicity, irritation, allergic reactions or other problems or complications of the disease are commensurate with a reasonable benefit/risk ratio.
- pharmaceutical composition refers to a biologically active compound optionally mixed with at least one pharmaceutically acceptable chemical component or agent.
- the pharmaceutically acceptable chemical component or agent is the “carrier”, which helps For introducing the compound into cells or tissues, it includes, but is not limited to, stabilizers, diluents, suspending agents, thickeners, and/or excipients.
- salts in the present invention may include metal salts, ammonium salts, salts with organic bases, salts with inorganic acids, salts with organic acids, salts with basic or acidic amino acids, etc. .
- metal salts include, but are not limited to, alkali metal salts, such as sodium salt, potassium salt, etc.; alkaline earth metal salts, such as calcium salt, magnesium salt, barium salt, etc.; aluminum salt, and the like.
- Non-limiting examples of salts formed with organic bases include, but are not limited to, trimethylamine, triethylamine, pyridine, picoline, 2,6-lutidine, ethanolamine, diethanolamine, triethanolamine, cyclohexylamine, Dicyclohexylamine and other salts.
- Non-limiting examples of salts formed with inorganic acids include, but are not limited to, salts formed with hydrochloric acid, hydrobromic acid, nitric acid, sulfuric acid, phosphoric acid, and the like.
- Non-limiting examples of salts formed with organic acids include, but are not limited to, formic acid, acetic acid, trifluoroacetic acid, lactic acid, fumaric acid, mandelic acid, oxalic acid, malic acid, maleic acid, tartaric acid, citric acid, succinic acid, Salts formed by methanesulfonic acid, benzenesulfonic acid, and p-toluenesulfonic acid.
- Non-limiting examples of salts formed with basic amino acids include, but are not limited to, salts formed with arginine, lysine, ornithine and the like.
- Non-limiting examples of salts formed with acidic amino acids include, but are not limited to, salts formed with aspartic acid, glutamic acid, and the like.
- salts can be synthesized from parent compounds containing acid radicals or bases by conventional chemical methods. Generally, such salts are prepared by reacting these compounds in free acid or base form with a stoichiometric amount of appropriate base or acid in water or an organic solvent or a mixture of both. Generally, non-aqueous media such as ether, ethyl acetate, ethanol, isopropanol, or acetonitrile are preferred.
- solvate refers to a physical aggregate formed by a compound of the present invention and one or more solvent molecules. This physical aggregate includes varying degrees of ions and covalent bonds, such as hydrogen bonds. It has been shown that this solvate can be separated, for example, when one or more solvent molecules are mixed in the crystal lattice.
- Solvate includes both the solvent phase and the separable solvate. There are many examples of corresponding solvates, including ethanol solvates, methanol solvates and the like.
- “Hydrate” is a solvate that uses water (H 2 O) molecules as a solvent.
- One or more compounds in the present invention can be prepared as solvates at will. The preparation of solvates is well known. For example, M.
- active metabolite refers to an active derivative of the compound formed when the compound is metabolized.
- polymorphs refers to compounds of the present invention that exist in different crystal lattice forms.
- isotopic label refers to a compound of the present invention that has an isotopic label.
- the isotopes in the compound of the present invention may include various isotopes of elements such as H, C, N, O, P, F, S, such as 2 H, 3 H, 13 C, 14 C, 15 N, 18 O, 17 O, 31 P, 32 P, 35 S, 18 F and 36 S.
- the term "isomer” refers to isomers produced by different arrangements of atoms in a molecule in space.
- the compounds of the present invention contain structures such as asymmetric or chiral centers and double bonds. Therefore, the compounds of the present invention may include optical isomers, geometric isomers, tautomers, atropisomers and other isomers.
- the body forms, these isomers and their single isomers, racemates, etc. are all included in the scope of the present invention.
- optically active (R)- and (S)-isomers and D and L isomers can be prepared by chiral resolution, chiral synthesis or chiral reagents or other conventional techniques. body.
- it can be converted into diastereomers by reacting with an appropriate optically active substance (such as a chiral alcohol or Mosher ⁇ s Moss acid chloride), and then separated and converted (such as hydrolyzed) into the corresponding single isomer body.
- an appropriate optically active substance such as a chiral alcohol or Mosher ⁇ s Moss acid chloride
- separation can also be performed by a chromatographic column.
- compositions can be prepared in a manner well known in the pharmaceutical field, and they can be administered or administered by various routes, depending on whether local or systemic treatment is required and the area to be treated. It can be delivered locally (for example, transdermal, skin, eye, and mucous membranes including intranasal, vaginal and rectal delivery), lung (for example, by inhalation or insufflation of powder or aerosol, including through a nebulizer; intratracheal, intranasal), Oral or parenteral administration.
- Parenteral administration includes intravenous, intraarterial, subcutaneous, intraperitoneal or intramuscular injection or infusion; or intracranial, such as intrathecal or intracerebroventricular administration.
- the pharmaceutical composition herein includes but is not limited to the following forms: tablets, pills, powders, lozenges, sachets, cachets, elixirs, suspensions, emulsions, solutions, syrups, aerosols (solid Or it can be dissolved in a liquid vehicle), ointment, soft and hard gelatin capsules, suppositories, sterile injection solutions and sterile packaging powders.
- the pharmaceutical composition herein may be formulated in a unit dosage form, and each dosage may contain about 0.1 to 1000 mg, usually about 5 to 1000 mg of active ingredient, more usually about 100 to 500 mg of active ingredient.
- unit dosage form refers to physically separated single dosage units suitable for use in human patients and other mammals, each unit containing a predetermined amount of active substance mixed with a suitable pharmaceutical carrier calculated to produce the desired therapeutic effect.
- the compound described in the present invention can be prepared by the following method.
- the following methods and examples are to illustrate these methods. These procedures and examples should not be construed as limiting the present invention in any way.
- the compounds described herein can also be synthesized using standard synthesis techniques known to those skilled in the art, or methods known in the art can be used in combination with the methods described herein.
- the reactions described herein can be monitored according to any suitable method known in the art.
- a broad spectrum method such as nuclear magnetic resonance spectroscopy (such as 1 H or 13 C), infrared spectroscopy, spectrophotometry (such as UV-visible light), mass spectrometry, etc., or by chromatography such as high performance liquid chromatography (HPLC) or thin layer Chromatography (TLC) monitors product formation.
- HPLC high performance liquid chromatography
- TLC thin layer Chromatography
- Step C 1-(2-(1-Methyl-1H-pyrazol-4-yl)-2-oxoethyl)-1H-pyrazole-3,5-dicarboxylic acid diethyl ester
- the 2-bromo-1-(1-methyl-1H-pyrazol-4-yl)ethan-1-one (21.5g, 106mmol) and 1H-pyrazole-3,5-two Cs 2 CO 3 (46 g, 140 mmol) was added to the mixture of diethyl formate (25.1 g, 118 mmol) in DMF (200 mL). After reacting at about 20°C for 18 hours, it was diluted with water (200 mL) and extracted with DCM (3 ⁇ 200 mL). The combined DCM extract was dried over anhydrous sodium sulfate and concentrated. The residue was purified by chromatography to obtain the title compound as a yellow solid (31.1 g, yield 93%).
- Step D 4-hydroxy-6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazine-2-carboxylic acid ethyl ester
- Step E 4-Hydroxy-6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazine-2-carboxylic acid
- Step F 6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-ol
- Step G 4-Chloro-6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazine (Compound I1)
- Step A p-methoxyphenol cyanoester
- Step B 4-Chloro-3-iodo-6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazine
- Step C 4-Chloro-6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazine-3-carbonitrile (Compound I2)
- Step A tert-Butyl 3-(3-amino-4-bromo-1H-pyrazol-1-yl)-3-(cyanomethyl)azetidine-1-carboxylate
- Step B 3-(3-Amino-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole-1 -Yl)-3-(cyanomethyl)azetidine-1-carboxylic acid tert-butyl ester (Compound I3)
- Step A 2-(3-(3-Amino-4-bromo-1H-pyrazol-1-yl)-1-(ethylsulfonyl)azetidin-3-yl)acetonitrile
- Step B 2-(3-(3-Amino-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyridine (Azol-1-yl)-1-(ethylsulfonyl)azetidin-3-yl)acetonitrile (Compound I4 )
- Step A 2-(3-(3-Amino-4-bromo-1H-pyrazol-1-yl)-1-(isopropylsulfonyl)azetidin-3-yl)acetonitrile
- Step B 2-(3-(3-Amino-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyridine (Azol-1-yl)-1-(isopropylsulfonyl)azetidin-3-yl)acetonitrile (Compound I5)
- Step A 2-(1-(3-Amino-4-bromo-1H-pyrazol-1-yl)-3-(benzyloxy)cyclobutyl)acetonitrile (cis and trans)
- Step B 2-(1-(3-amino-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyridine (Azol-1-yl)-3-(benzyloxy)cyclobutyl)acetonitrile (compound I6, cis and trans)
- Step A (1r,3r)-3-(3-amino-4-bromo-1H-pyrazol-1-yl)-3-(cyanomethyl)cyclobutyl-1-carbonitrile and (1s, 3s)-3-(3-amino-4-bromo-1H-pyrazol-1-yl)-3-(cyanomethyl)cyclobutyl-1-carbonitrile
- Step B (1r,3r)-3-(3-amino-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)- 1H-pyrazol-1-yl)-3-(cyanomethyl)cyclobutyl-1-carbonitrile (compound I7) and (1s,3s)-3-(3-amino-4-(4,4 ,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazol-1-yl)-3-(cyanomethyl)cyclobutyl- 1-carbonitrile (compound I8 )
- Step B (1r,3r)-3-(3-bromo-1H-pyrrole[3,2-c]pyridin-1-yl)-3-(cyanomethyl)cyclobutyl-1-carbonitrile ( Compound I9) and (1s, 3s)-3-(3-bromo-1H-pyrrole[3,2-c]pyridin-1-yl)-3-(cyanomethyl)cyclobutyl-1-carbonitrile (Compound I10)
- Step A 4-Methoxy-6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyridine
- reaction mixture was quenched by adding water, extracted with ethyl acetate, and the organic phases were combined, washed once with water and once with saturated brine, dried over anhydrous sodium sulfate, filtered, concentrated in vacuo, and purified by column chromatography to obtain the title compound ( 1.0g, yield 100%), directly used in the next reaction.
- Step B 4-Hydroxy-6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyridine
- reaction mixture was slowly poured into ice water to quench After extraction with ethyl acetate, the organic phases were combined, washed once with water and once with saturated brine, dried over anhydrous sodium sulfate, filtered, concentrated under reduced pressure in vacuo, and purified by column chromatography to obtain the title compound (0.9g, yield 96%) , Directly used in the next reaction.
- Step A 1-(Cyanomethyl)-1H-pyrazole-5-carboxylic acid ethyl ester
- Step B 1-(2-Amino-2-oxoethyl)-1H-pyrazole-5-carboxylic acid ethyl ester
- Step A 3-(3-Amino-4-(6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)-1H- Pyrazol-1-yl)-3-(cyanomethyl)azetidine-1-carboxylic acid tert-butyl ester
- Step B 2-(3-(3-amino-4-(6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl) -1H-pyrazol-1-yl)azetidin-3-yl)acetonitrile
- Step C 2,2'-(3-(3-amino-4-(6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazine-4 -Yl)-1H-pyrazol-1-yl)azetidine-1,3-diyl)diacetonitrile
- reaction was quenched by adding water to the reaction mixture, extracted with ethyl acetate, combined the organic phases, washed once with water, washed once with saturated brine, dried over anhydrous sodium sulfate, filtered, and reduced in vacuo Concentrated and purified by column chromatography to obtain the title compound as a white foam solid (118 mg, yield 26%).
- Step A 2-(1-(3-amino-4-(6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl) -1H-pyrazol-1-yl)-3-(benzyloxy)cyclobutyl)acetonitrile
- Step B 2-((1r,3s)-1-(3-amino-4-(6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyridine (Azin-4-yl)-1H-pyrazol-1-yl)-3-hydroxycyclobutyl)acetonitrile (trans isomer) and 2-((1s,3r)-1-(3-amino-4- (6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)-1H-pyrazol-1-yl)-3-hydroxy ring Butyl) acetonitrile (cis isomer)
- the 2-(1-(3-amino-4-(6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazine -4-yl)-1H-pyrazol-1-yl)-3-hydroxycyclobutyl)acetonitrile (cis and trans) (105mg, 0.27mmol) was dissolved in a small amount of THF (10mL), added to the reaction system Butylammonium bromide (261mg, 0.81mmol), 1M NaOH aqueous solution (3mL) and dimethyl sulfate (170mg, 1.35mmol); seal the reaction flask and stir vigorously at 20°C for about 1 hour, add additional dimethyl sulfate Ester (170mg, 1.35mmol) and tetrabutylammonium bromide (261mg, 0.81mmol).
- reaction mixture is diluted with water, extracted with ethyl acetate, the organic phases are combined, washed once with water and once with saturated brine, dried over anhydrous sodium sulfate, filtered, concentrated under reduced pressure in vacuo, and purified by column chromatography (1r,3r)-3-(3-amino-4-(6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl )-1H-pyrazol-1-yl)-3-(cyanomethyl)cyclobutyl-1-carbonitrile (130 mg, yield 33%).
- TLC monitors the completion of the reaction and adds to the reaction mixture Quenched with water, extracted with ethyl acetate, combined the organic phases, washed once with water, washed once with saturated brine, dried over anhydrous sodium sulfate, filtered, concentrated in vacuo, and purified by column chromatography to obtain the title compound (8mg, yield 16 %).
- Step A (1r,3r)-3-(3-amino-4-(6-bromo-[1,2,4]triazolo[1,5-a]pyrazin-8-yl)-1H -Pyrazol-1-yl)-3-(cyanomethyl)cyclobutane-1-carbonitrile
- Step B (1r,3r)-3-(3-amino-4-(6-(1-methyl-1H-pyrazol-4-yl)-[1,2,4]triazolo[1 ,5-a)pyrazin-8-yl)-1H-pyrazol-1-yl)-3-(cyanomethyl)cyclobutane-1-carbonitrile
- reaction mixture was quenched by adding water, extracted with ethyl acetate, combined the organic phases, washed once with water, washed once with saturated brine, dried over anhydrous sodium sulfate, filtered, concentrated under reduced pressure in a column Chromatographic purification gave the title compound (43mg, yield 37%).
- reaction mixture was quenched by adding water, extracted with ethyl acetate, combined the organic phases, washed once with water, washed once with saturated brine, dried over anhydrous sodium sulfate, filtered, concentrated under reduced pressure in a column Chromatographic purification gave the title compound (57mg, yield 50%).
- Step A (1r,3r)-3-(3-amino-4-(6-chloropyrazolo[1,5-a]pyrazin-4-yl)-1H-pyrazol-1-yl)- 3-(cyanomethyl)cyclobutane-1-carbonitrile
- Step B (1r,3r)-3-(3-amino-4-(6-(2-hydroxy-2-methylpropoxy)pyrazolo[1,5-a]pyrazin-4-yl )-1H-pyrazol-1-yl)-3-(cyanomethyl)cyclobutane-1-carbonitrile
- reaction mixture was quenched by adding water, extracted with ethyl acetate, combined organic phases, washed once with water and once with saturated brine , Dried over anhydrous sodium sulfate, filtered, concentrated in vacuo, and purified by column chromatography to obtain the title compound (34mg, yield 30%).
- Step A (1s,3s)-3-(cyanomethyl)-3-(3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolane- 2-yl)-1H-pyrrolo[3,2-c]pyridin-1-yl)cyclobutane-1-carbonitrile
- Step B (1s,3s)-3-(cyanomethyl)-3-(3-(6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a ]Pyrazin-4-yl)-1H-pyrrolo[3,2-c]pyridin-1-yl)cyclobutane-1-carbonitrile
- Step A (1r,3r)-3-(cyanomethyl)-3-(3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolane- 2-yl)-1H-pyrrolo[3,2-c]pyridin-1-yl)cyclobutane-1-carbonitrile
- Step B (1r,3r)-3-(cyanomethyl)-3-(3-(6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a ]Pyrazin-4-yl)-1H-pyrrolo[3,2-c]pyridin-1-yl)cyclobutane-1-carbonitrile
- step A The reaction mixture in the above experiment step A was cooled to room temperature, and 4-chloro-6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyridine was added to the reaction system.
- Oxazine (355mg, 1.5mmol), 2M Na 2 CO 3 aqueous solution (2.3mL) and [1,1'-bis(diphenylphosphino)ferrocene]palladium dichloride (110mg, 0.15mmol)
- the reaction The system was bubbling with nitrogen for 3 minutes, and reacted at 95°C for 2 hours under nitrogen balloon protection, and reacted at 110°C for 2 hours; TLC monitored the disappearance of the raw materials, added water to the reaction mixture for dilution, extracted with ethyl acetate, combined the organic phases, and washed with water Once, washed with saturated brine, dried over anhydrous sodium sulfate, filtered, concentrated in vacuo, and purified by column chromat
- Step A (1s,3s)-3-(cyanomethyl)-3-(5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolane- 2-yl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl)cyclobutane-1-carbonitrile
- Step B (1s,3s)-3-(cyanomethyl)-3-(5-(6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a ]Pyrazin-4-yl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl)cyclobutane-1-carbonitrile
- Step A (1r,3r)-3-(cyanomethyl)-3-(5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolane- 2-yl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl)cyclobutane-1-carbonitrile
- Step B (1r,3r)-3-(cyanomethyl)-3-(5-(6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a ]Pyrazin-4-yl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl)cyclobutane-1-carbonitrile
- step A The reaction mixture in the above experiment step A was cooled to room temperature, and 4-chloro-6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyridine was added to the reaction system.
- Oxazine 400mg, 1.7mmol
- 2M Na 2 CO 3 aqueous solution 2.3mL
- [1,1'-bis(diphenylphosphino)ferrocene]palladium dichloride 100mg, 0.14mmol
- TLC monitored the disappearance of the raw materials, added water to the reaction mixture for dilution, extracted with ethyl acetate, combined the organic phases, and washed with water Once, washed with saturated brine, dried over anhydrous sodium sulfate, filtered, concentrated in vacuo, and purified by column chromatography to obtain the title compound
- MSA mobility detection technology
- the core of the screening platform is MSA based on microfluidic chip technology, which applies the basic concepts of capillary electrophoresis to a microfluidic environment.
- the experimental substrate is a polypeptide with a fluorescent label. Under the catalysis of the enzyme in the reaction system, the substrate is converted into a product, and the charge on the substrate changes accordingly. MSA uses the difference in charge between the substrate and the product to separate the two and detect them separately.
- the compound powder was dissolved in 100% DMSO to prepare a 10 mM stock solution.
- the initial test concentration of the compound is 10,000nM or 1000nM, 3 times or 4 times dilution, 10 concentrations, multiple well detection.
- Baricitinib (Selleckchem, Cat. S2851) was used as a positive control compound. Dilute the compound with the final concentration of 5nM/0.125nM/0.5nM/2.5nM JAK1/JAK2/JAK3/Tyk2 kinase (Carna, Cat.08-144/08-045/08-046/08-147) in Optiplate -384F well plate is mixed and incubated at room temperature for 10 minutes.
- ATP with a final concentration of 1 mM and Kinase substrate 30 were added at a final concentration of 3 ⁇ M, mixed, and reacted at room temperature for 20 minutes. After adding the stop test solution to terminate the enzymatic reaction, use Caliper EZ Reader II to read the conversion rate.
- Conversion%_sample is the conversion rate reading of the sample
- Conversion%_min the average value of the negative control wells, which represents the conversion rate readings of the wells without enzyme activity
- Conversion%_max the average value of the positive control wells, represents the conversion rate readings of the wells without compound inhibition .
- Fitting the dose-response curve take the log value of the concentration as the X-axis, and the percentage inhibition rate on the Y-axis. Use the analysis software GraphPad Prism 5 log(inhibitor) vs.response-Variable slope to fit the dose-response curve to obtain each compound IC 50 value for inhibition of enzyme activity.
Abstract
Description
Claims (17)
- 一种如通式(AI)所示的化合物或其药学上可接受的盐、溶剂化物、活性代谢物、多晶型物、同位素标记物或异构体,其中,WR 1表示-(CR 5R 1)-或-(NR 1)-;A表示-OR”或 X、Y、Z各自独立地表示-O-、-S-、-(CO)-、-(CS)-、-(CR 6)=、-(CR 6R 7)-、-N=或-(NR 6)-,且使所形成的五元环为不饱和环;其中的R 6、R 7各自独立地表示取代或未取代的氢、卤素、C 1~6烷基、C 1~6烷氧基、C 1~6卤代烷基、羟基、巯基、氨基、氰基、C 1~4亚烷基羟基、C 1~4亚烷基巯基、C 1~4亚烷基氨基、C 1~4亚烷基氰基、-NR 9COR 10、-COR 9或-CONR 9R 10;R”表示取代有羟基、甲氧基或氨基的C 1-C 6烷基;R表示卤素、取代或未取代的-NR 9R 10,或者R’与R以及它们所连接的环上原子一起形成六元或五元的芳香环或杂芳环;XR’表示-(N)-或-(CR’)-,其中,当XR’表示-(CR’)-时,R’与R以及它们所连接的环上原子一起形成六元或五元的芳香环或杂芳环;YR 3表示-(N)-或-(CR 3)-;Z表示-N-或-CR 3-;R 1表示-(CH 2) n-R 1’,R 1’表示取代或未取代的氢、卤素、C 1~6烷基、C 1~6烷氧基、C 1~6卤代烷基、羟基、巯基、氨基、氰基、C 3~8环烷基、C 3~8杂环基、C 6~20芳基、C 3~20杂芳基、-NR 9COR 10、-CONR 9R 10、-COR 9、-SOR 9或-SO 2R 9,n表示0~4的整数;R 2~R 5各自独立地表示取代或未取代的氢、卤素、C 1~6烷基、C 1~6烷氧基、C 1~6卤代烷基、羟基、巯基、氨基或氰基;R 8表示-(CH 2) n-R 8’,R 8’表示取代或未取代的氢、卤素、C 1~6烷基、C 1~6烷氧基、 C 1~6卤代烷基、羟基、巯基、氰基或-NR 9R 10,n表示0~4的整数;R 9、R 10各自独立地表示取代或未取代的氢、卤素、C 1~6烷基、C 1~6烷氧基、C 1~6卤代烷基、羟基、巯基、氨基、氰基、C 3~8环烷基或C 3~8杂环基;上述基团可选的取代基选自卤素、C 1~6烷基、C 1~6卤代烷基、C 1~6烷氧基、C 1~6烷硫基、C 3~8环烷基、C 3~8杂环基、C 6~20芳基、C 3~20杂芳基、C 1~6烷基酯基、C 1~6烷基酰基、C 1~6烷基磺酰基、氨基、羟基、巯基、羧基、硝基、酰胺基或氰基。
- 根据权利要求1所述的化合物或其药学上可接受的盐、溶剂化物、活性代谢物、多晶型物、同位素标记物或异构体,其中,所述化合物为如通式(Ⅰ)所示的化合物,其中,WR 1表示-(CR 5R 1)-或-(NR 1)-;A表示 X、Y、Z各自独立地表示-O-、-S-、-(CO)-、-(CS)-、-(CR 6)=、-(CR 6R 7)-、-N=或-(NR 6)-,且使所形成的五元环为不饱和环;其中的R 6、R 7各自独立地表示取代或未取代的氢、卤素、C 1~6烷基、C 1~6烷氧基、C 1~6卤代烷基、羟基、巯基、氨基、氰基、C 1~4亚烷基羟基、C 1~4亚烷基巯基、C 1~4亚烷基氨基、C 1~4亚烷基氰基、-NR 9COR 10、-COR 9或-CONR 9R 10;R表示取代或未取代的-NR 9R 10;R 1表示-(CH 2) n-R 1’,R 1’表示取代或未取代的氢、卤素、C 1~6烷基、C 1~6烷氧基、C 1~6卤代烷基、羟基、巯基、氨基、氰基、C 3~8环烷基、C 3~8杂环基、C 6~20芳基、C 3~20杂芳基、-NR 9COR 10、-CONR 9R 10、-COR 9、-SOR 9或-SO 2R 9,n表示0~4的整数;R 2~R 5各自独立地表示取代或未取代的氢、卤素、C 1~6烷基、C 1~6烷氧基、C 1~6卤代烷基、羟基、巯基、氨基或氰基;R 8表示-(CH 2) n-R 8’,R 8’表示取代或未取代的氢、卤素、C 1~6烷基、C 1~6烷氧基、C 1~6卤代烷基、羟基、巯基、氰基或-NR 9R 10,n表示0~4的整数;R 9、R 10各自独立地表示取代或未取代的氢、卤素、C 1~6烷基、C 1~6烷氧基、C 1~6卤代 烷基、羟基、巯基、氨基、氰基、C 3~8环烷基或C 3~8杂环基;上述基团可选的取代基选自卤素、C 1~6烷基、C 1~6卤代烷基、C 1~6烷氧基、C 1~6烷硫基、C 3~8环烷基、C 3~8杂环基、C 6~20芳基、C 3~20杂芳基、C 1~6烷基酯基、C 1~6烷基酰基、C 1~6烷基磺酰基、氨基、羟基、巯基、羧基、硝基、酰胺基或氰基。
- 根据权利要求1所述的化合物或其药学上可接受的盐、溶剂化物、活性代谢物、多晶型物、同位素标记物或异构体,其中,所述化合物为如通式(Ⅰ)所示的化合物,其中,WR 1表示-(CR 5R 1)-或-(NR 1)-;A表示-OR”,其中R”表示取代有羟基、甲氧基或氨基的C 1-C 6烷基;R表示卤素、取代或未取代的-NR 9R 10;R 1表示-(CH 2) n-R 1’,R 1’表示取代或未取代的氢、卤素、C 1~6烷基、C 1~6烷氧基、C 1~6卤代烷基、羟基、巯基、氨基、氰基、C 3~8环烷基、C 3~8杂环基、C 6~20芳基、C 3~20杂芳基、-NR 9COR 10、-CONR 9R 10、-COR 9、-SOR 9或-SO 2R 9,n表示0~4的整数;R 2~R 5各自独立地表示取代或未取代的氢、卤素、C 1~6烷基、C 1~6烷氧基、C 1~6卤代 烷基、羟基、巯基、氨基或氰基;R 8表示-(CH 2) n-R 8’,R 8’表示取代或未取代的氢、卤素、C 1~6烷基、C 1~6烷氧基、C 1~6卤代烷基、羟基、巯基、氰基或-NR 9R 10,n表示0~4的整数;R 9、R 10各自独立地表示取代或未取代的氢、卤素、C 1~6烷基、C 1~6烷氧基、C 1~6卤代烷基、羟基、巯基、氨基、氰基、C 3~8环烷基或C 3~8杂环基;上述基团可选的取代基选自卤素、C 1~6烷基、C 1~6卤代烷基、C 1~6烷氧基、C 1~6烷硫基、C 3~8环烷基、C 3~8杂环基、C 6~20芳基、C 3~20杂芳基、C 1~6烷基酯基、C 1~6烷基酰基、C 1~6烷基磺酰基、氨基、羟基、巯基、羧基、硝基、酰胺基或氰基。
- 根据权利要求1-6任一项所述的化合物或其药学上可接受的盐、溶剂化物、活性代谢物、多晶型物、同位素标记物或异构体,其中,所述R表示-NH 2。
- 根据权利要求1-7任一项所述的化合物或其药学上可接受的盐、溶剂化物、活性代谢物、多晶型物、同位素标记物或异构体,其中,所述R 1表示-(CH 2) n-R 1’,n表示0、1或2。
- 根据权利要求8所述的化合物或其药学上可接受的盐、溶剂化物、活性代谢物、多晶型物、同位素标记物或异构体,其中,所述R 1’表示氢、C 1~4烷基、C 1~4烷氧基、C 1~4卤代烷基、羟基、氰基、C 3~6环烷基、C 3~5杂芳基、-COR 9或-SO 2R 9;其中的R 9表示C 1~4烷基、C 1~4烷氧基、C 1~4卤代烷基或C 3~6环烷基。
- 一种药物组合物,其包含权利要求1-10任一项所述的化合物或其药学上可接受的盐、溶剂化物、活性代谢物、多晶型物、同位素标记物、异构体或前药,以及药学可接受的载体。
- 权利要求1-10任一项所述的化合物或其药学上可接受的盐、溶剂化物、活性代 谢物、多晶型物、同位素标记物、异构体或前药,以及权利要求11所述的药物组合物在制备用于治疗两面神激酶(JAK)介导的疾病的药物中的用途。
- 根据权利要求12所述的用途,其中,所述两面神激酶为Tyk2激酶。
- 根据权利要求12所述的用途,其中,所述JAK酶介导的疾病包括肿瘤或自身免疫性疾病。
- 根据权利要求12所述的用途,其中,所述JAK酶介导的疾病包括白血病、非小细胞肺癌、结肠癌、淋巴瘤、骨髓增殖性肿瘤、骨髓异常综合征、类风湿性关节炎、银屑病性关节炎、移植物抗宿主病、非感染性葡萄膜炎、克罗恩病、溃疡性结肠炎、强直性脊柱炎、银屑病、特异性皮炎、白癜风、瘙痒症、硬皮病、斑秃、全秃、普秃、雄激素性秃发、白塞病、干眼症。
- 一种用于治疗两面神激酶(JAK)介导的疾病的方法,所述方法包括向有需要此治疗的受试者给药有效量的权利要求1-10任一项所述的化合物或其药学上可接受的盐、溶剂化物、活性代谢物、多晶型物、同位素标记物、异构体或前药,以及权利要求11所述的药物组合物。
- 根据权利要求16所述的方法,其中,所述JAK酶介导的疾病包括白血病、非小细胞肺癌、结肠癌、淋巴瘤、骨髓增殖性肿瘤、骨髓异常综合征、类风湿性关节炎、银屑病性关节炎、移植物抗宿主病、非感染性葡萄膜炎、克罗恩病、溃疡性结肠炎、强直性脊柱炎、银屑病、特异性皮炎、白癜风、瘙痒症、硬皮病、斑秃、全秃、普秃、雄激素性秃发、白塞病、干眼症。
Priority Applications (9)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020217036228A KR20210149151A (ko) | 2019-04-12 | 2020-04-10 | 피라졸로피라진 유래 화합물, 의약 조성물 및 그의 용도 |
BR112021020339A BR112021020339A2 (pt) | 2019-04-12 | 2020-04-10 | Compostos derivados de pirazolopirazina, composição farmacêutica, e uso dos mesmos |
CN202080027882.4A CN113924301A (zh) | 2019-04-12 | 2020-04-10 | 一种吡唑并吡嗪衍生的化合物、药物组合物以及其用途 |
EP20788562.5A EP3954689B1 (en) | 2019-04-12 | 2020-04-10 | Pyrazolopyrazine derived compounds, pharmaceutical composition and use thereof |
AU2020256720A AU2020256720B2 (en) | 2019-04-12 | 2020-04-10 | Pyrazolopyrazine derived compounds, pharmaceutical composition and use thereof |
JP2021559128A JP7256291B2 (ja) | 2019-04-12 | 2020-04-10 | ピラゾロピラジン誘導の化合物、医薬組成物およびその使用 |
CA3136468A CA3136468A1 (en) | 2019-04-12 | 2020-04-10 | Pyrazolopyrazine derived compounds and pharmaceutical compositions used as jak inhibitors |
US17/601,843 US20220204513A1 (en) | 2019-04-12 | 2020-04-10 | Pyrazolopyrazine derived compounds, pharmaceutical composition and use thereof |
MX2021012487A MX2021012487A (es) | 2019-04-12 | 2020-04-10 | Compuestos derivados de pirazolopirazina, composicion farmaceutica y uso de la misma. |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910294408 | 2019-04-12 | ||
CN201910294408.7 | 2019-04-12 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2020207476A1 true WO2020207476A1 (zh) | 2020-10-15 |
Family
ID=72750940
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2020/084243 WO2020207476A1 (zh) | 2019-04-12 | 2020-04-10 | 一种吡唑并吡嗪衍生的化合物、药物组合物以及其用途 |
Country Status (10)
Country | Link |
---|---|
US (1) | US20220204513A1 (zh) |
EP (1) | EP3954689B1 (zh) |
JP (1) | JP7256291B2 (zh) |
KR (1) | KR20210149151A (zh) |
CN (1) | CN113924301A (zh) |
AU (1) | AU2020256720B2 (zh) |
BR (1) | BR112021020339A2 (zh) |
CA (1) | CA3136468A1 (zh) |
MX (1) | MX2021012487A (zh) |
WO (1) | WO2020207476A1 (zh) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2022121825A1 (zh) * | 2020-12-07 | 2022-06-16 | 嘉兴特科罗生物科技有限公司 | 一种三氮唑并吡嗪类化合物及其用途 |
WO2023076161A1 (en) | 2021-10-25 | 2023-05-04 | Kymera Therapeutics, Inc. | Tyk2 degraders and uses thereof |
WO2023083200A1 (zh) * | 2021-11-12 | 2023-05-19 | 南京明德新药研发有限公司 | 吡唑并环化合物及其应用 |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20080312258A1 (en) * | 2007-06-13 | 2008-12-18 | Incyte Corporation | METABOLITES OF THE JANUS KINASE INHIBITOR (R)-3-(4-(7H-PYRROLO[2,3-d]PYRIMIDIN-4-YL)-1H-PYRAZOL-1-YL)-3-CYCLOPENTYLPROPANENITRILE |
WO2011101161A1 (en) * | 2010-02-18 | 2011-08-25 | Almirall, S.A. | Pyrazole derivatives as jak inhibitors |
WO2011130146A1 (en) * | 2010-04-14 | 2011-10-20 | Array Biopharma Inc. | 5, 7-substituted-imidazo [1, 2-c] pyrimidines as inhibitors of jak kinases |
WO2013055645A1 (en) * | 2011-10-12 | 2013-04-18 | Array Biopharma Inc. | 5,7-substituted-imidazo[1,2-c]pyrimidines |
WO2016090285A1 (en) * | 2014-12-05 | 2016-06-09 | Array Biopharma Inc. | 4,6-SUBSTITUTED-PYRAZOLO[1,5-a]PYRAZINES AS JANUS KINASE INHIBITORS |
WO2017144995A1 (en) * | 2016-02-24 | 2017-08-31 | Pfizer Inc. | Pyrazolo[1,5-a]pyrazin-4-yl derivatives as jak-inhibitors |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2019034973A1 (en) | 2017-08-14 | 2019-02-21 | Pfizer Inc. | PYRAZOLO [1,5-A] PYRAZIN-4-YL AND RELATED DERIVATIVES |
-
2020
- 2020-04-10 WO PCT/CN2020/084243 patent/WO2020207476A1/zh unknown
- 2020-04-10 CN CN202080027882.4A patent/CN113924301A/zh active Pending
- 2020-04-10 BR BR112021020339A patent/BR112021020339A2/pt unknown
- 2020-04-10 EP EP20788562.5A patent/EP3954689B1/en active Active
- 2020-04-10 MX MX2021012487A patent/MX2021012487A/es unknown
- 2020-04-10 JP JP2021559128A patent/JP7256291B2/ja active Active
- 2020-04-10 AU AU2020256720A patent/AU2020256720B2/en active Active
- 2020-04-10 US US17/601,843 patent/US20220204513A1/en active Pending
- 2020-04-10 KR KR1020217036228A patent/KR20210149151A/ko not_active Application Discontinuation
- 2020-04-10 CA CA3136468A patent/CA3136468A1/en active Pending
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20080312258A1 (en) * | 2007-06-13 | 2008-12-18 | Incyte Corporation | METABOLITES OF THE JANUS KINASE INHIBITOR (R)-3-(4-(7H-PYRROLO[2,3-d]PYRIMIDIN-4-YL)-1H-PYRAZOL-1-YL)-3-CYCLOPENTYLPROPANENITRILE |
WO2011101161A1 (en) * | 2010-02-18 | 2011-08-25 | Almirall, S.A. | Pyrazole derivatives as jak inhibitors |
WO2011130146A1 (en) * | 2010-04-14 | 2011-10-20 | Array Biopharma Inc. | 5, 7-substituted-imidazo [1, 2-c] pyrimidines as inhibitors of jak kinases |
WO2013055645A1 (en) * | 2011-10-12 | 2013-04-18 | Array Biopharma Inc. | 5,7-substituted-imidazo[1,2-c]pyrimidines |
WO2016090285A1 (en) * | 2014-12-05 | 2016-06-09 | Array Biopharma Inc. | 4,6-SUBSTITUTED-PYRAZOLO[1,5-a]PYRAZINES AS JANUS KINASE INHIBITORS |
WO2017144995A1 (en) * | 2016-02-24 | 2017-08-31 | Pfizer Inc. | Pyrazolo[1,5-a]pyrazin-4-yl derivatives as jak-inhibitors |
Non-Patent Citations (6)
Title |
---|
AL BINGHAM ET AL., CHEM. COMMUN., 2001, pages 603 - 604 |
CAREYSUNDBERG'S: "Advanced Organic Chemistry", vol. A, 2000, PLENUM PRESS |
E.C. VAN TONDER ET AL., AAPS PHARMSCITECH., vol. 5, no. 1, 2004 |
GREENEWUTS: "Protective Groups In Organic Synthesis", 1991, WILEY AND SONS |
M. CAIRA ET AL., J. PHARMACEUTICAL SCI., vol. 93, no. 3, 2004, pages 601 - 611 |
See also references of EP3954689A4 |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2022121825A1 (zh) * | 2020-12-07 | 2022-06-16 | 嘉兴特科罗生物科技有限公司 | 一种三氮唑并吡嗪类化合物及其用途 |
WO2023076161A1 (en) | 2021-10-25 | 2023-05-04 | Kymera Therapeutics, Inc. | Tyk2 degraders and uses thereof |
WO2023083200A1 (zh) * | 2021-11-12 | 2023-05-19 | 南京明德新药研发有限公司 | 吡唑并环化合物及其应用 |
Also Published As
Publication number | Publication date |
---|---|
EP3954689A4 (en) | 2023-01-04 |
EP3954689B1 (en) | 2024-04-24 |
EP3954689A1 (en) | 2022-02-16 |
AU2020256720B2 (en) | 2022-09-01 |
JP7256291B2 (ja) | 2023-04-11 |
CA3136468A1 (en) | 2020-10-15 |
CN113924301A (zh) | 2022-01-11 |
JP2022526599A (ja) | 2022-05-25 |
KR20210149151A (ko) | 2021-12-08 |
BR112021020339A2 (pt) | 2021-12-07 |
MX2021012487A (es) | 2021-11-12 |
AU2020256720A1 (en) | 2022-02-17 |
US20220204513A1 (en) | 2022-06-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN112105419B (zh) | 稠环化合物 | |
CN112119075B (zh) | 稠环化合物 | |
CN113004278B (zh) | 作为fgfr抑制剂的双环杂环 | |
CN109348715B (zh) | 作为tam抑制剂的吡咯并三嗪化合物 | |
WO2021037018A1 (zh) | 二氢或四氢喹唑啉类化合物及其中间体、制备方法和应用 | |
TWI643857B (zh) | 作為jak1抑制劑之哌啶-4-基三亞甲亞胺衍生物 | |
WO2015022926A1 (ja) | 新規な縮合ピリミジン化合物又はその塩 | |
CN109867676B (zh) | 一种吡咯并嘧啶衍生的化合物、药物组合物以及其用途 | |
BR112014017749B1 (pt) | Composto alquinilbenzeno 3,5-dissubstituído e sal do mesmo | |
WO2022214053A1 (zh) | 泛素特异性蛋白酶1(usp1)抑制剂 | |
WO2020207476A1 (zh) | 一种吡唑并吡嗪衍生的化合物、药物组合物以及其用途 | |
WO2017035753A1 (zh) | 2-芳胺基吡啶、嘧啶或三嗪衍生物及其制备方法和用途 | |
WO2013118817A1 (ja) | キノリルピロロピリミジン化合物又はその塩 | |
WO2018010514A1 (zh) | 作为fgfr抑制剂的杂环化合物 | |
CN110294761A (zh) | 作为Trk激酶抑制剂的取代的吡唑并[1,5-a]嘧啶化合物 | |
CN109867675B (zh) | 一种吡咯并嘧啶衍生的化合物、药物组合物以及其用途 | |
WO2023067546A1 (en) | Novel bicyclic heteroaryl derivatives as sos1:kras proteinprotein interaction inhibitors | |
WO2020221209A1 (zh) | 一种cd73抑制剂,其制备方法和应用 | |
CN115916771A (zh) | 多靶点的抗肿瘤化合物及其制备方法和应用 | |
KR102513564B1 (ko) | 메닌-mll 상호작용의 아제판 억제제 | |
CN111763217B (zh) | 一类噻吩并氮杂环类化合物、制备方法和用途 | |
CN113563341B (zh) | 作为Trk抑制剂的取代的吡唑并[1,5-a]嘧啶化合物 | |
WO2024061118A1 (zh) | 大环含氮冠醚化合物及其作为蛋白激酶抑制剂的应用 | |
WO2022063050A1 (zh) | 吡唑类化合物及其制备方法和用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 20788562 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2021559128 Country of ref document: JP Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 3136468 Country of ref document: CA |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112021020339 Country of ref document: BR |
|
ENP | Entry into the national phase |
Ref document number: 20217036228 Country of ref document: KR Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2020788562 Country of ref document: EP Effective date: 20211112 |
|
ENP | Entry into the national phase |
Ref document number: 112021020339 Country of ref document: BR Kind code of ref document: A2 Effective date: 20211008 |
|
ENP | Entry into the national phase |
Ref document number: 2020256720 Country of ref document: AU Date of ref document: 20200410 Kind code of ref document: A |